Icecure Medical (ICCM) has released an update.
IceCure Medical reports positive outcomes from a large multi-institutional study on cryoablation for breast cancer patients ineligible for clinical trials, published in the American Journal of Roentgenology. The study, which included patients with higher risks like metastatic disease and large tumors, demonstrated high recurrence-free rates over three years and confirmed the safety and efficacy of IceCure’s ProSense® system as a non-surgical alternative for tumor treatment.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
